Back HCV Disease Progression

HCV Disease Progression

DDW 2015/EASL 2015: Statins Associated with Lower Risk of Death and Liver Decompensation

Hepatitis C patients with liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of U.S. veterans presented at the Digestive Disease Week meeting this week in Washington, DC, and at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Another recent study found that statins were associated with better response to hepatitis C treatment and lower risk of liver cancer.

alt

Read more:

EASL 2015: Another Study Confirms Detrimental Effects of Delaying Hepatitis C Treatment

Deferring antiviral therapy for hepatitis C until a person progresses to advanced liver disease has clear drawbacks including lower treatment effectiveness and an increased risk of clinical events and death, according to a study of U.S. veterans presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.

alt

Read more:

EASL 2015: Heavy Alcohol Use Is Strongest Predictor of Liver Damage and Death in French Hepatitis C Patients

People with hepatitis C have a much greater risk of liver-related hospitalization or death if they have an alcohol use disorder or another serious comorbidity such as HIV infection, chronic kidney disease, or cancer, according to an analysis of everyone hospitalized in France between 2008 and 2012 presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. In the absence of these problems, however, people with hepatitis C did not have an increased risk of death compared to the general population.

alt

Read more:

EASL 2015: Advanced Liver Damage Is Common Among People with Undiagnosed Hepatitis C

Around 1 in 5 people with hepatitis C in the U.S. who do not know of their infection may already have advanced liver damage and be in urgent need of treatment, according to a cross-sectional survey of participants in the National Health and Nutritional Examination Survey (NHANES) presented by Prowpanga Udompap at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.

alt

Read more: